Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Eden LSE:EDEN London Ordinary Share GB0001646941 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.15p -1.30% 11.35p 10.70p 12.00p 11.50p 11.00p 11.50p 271,250 15:16:17
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1.9 -0.8 -0.3 - 23.52

Eden Share Discussion Threads

Showing 6151 to 6173 of 6175 messages
Chat Pages: 247  246  245  244  243  242  241  240  239  238  237  236  Older
DateSubjectAuthorDiscuss
21/1/2019
22:06
The Chronology: the arrangement of events or dates in the order of their occurrence. Co-innovation and expansion of breakthrough technology for a natural pesticide and anti-microbial. Xinova Preliminary Results 31st May 2013 'We look forward to the launch of product sales in the not too distant future and to working closely with Bayer to extend the sales opportunities for those products and to explore other areas of interest to Bayer, outside of animal health'. Licence Agreement with SUMIAGRO 1st Dec 2014 Beyond this agreement and 3AEY, we look forward to developing other product opportunities with Sumi Agro France as well as with affiliated Sumitomo Corporation companies. " Sumi Agro France is a European affiliated company of the Japanese SUMITOMO CORPORATION group, one of the largest trading house in the World.‚ In 2012, Sumi Agro and Sipcam signed an alliance, creating a common platform for the development, marketing and distribution of products for Agriculture, covering all European markets. Agreement with Sipcam covering new products 20th May 2015 'Sean Smith, Chief Executive Officer of Eden, said: "We are pleased with the increase in activities with our partner, Sipcam.‚ This is clear evidence that we are realising the potential to expand the commercialisation of our products and grow the existing relationship with Sumitomo related companies around the world. Chairmans Report..19/3/18 'In the next twelve months , we expect to see significant progress being made with Sipcam for Eden's pipeline products as well as a ramp up in the development of SustaineTM the companies microencapsulation technology, with Sipcam and other interested parties'. Year-end trading update 15th Jan 2019 Sustaineä, Eden's patented, natural micro-encapsulation technology, is being evaluated by an increasing number of parties, including Sipcam, on a large and growing number of active ingredients used in crop protection. This technology represents significant medium-term potential for the Company, and we are pleased with the attention it is receiving in the hands of current and new collaborators.
supersonico
21/1/2019
09:51
Eden Throwing out clues to what the 7/2 Eden Quiz Night Questions will look like. Extra canapes for each right answer on the night.. Eden Research plc@edenresearch Eden's products are a perfect fit for IPM programmes... Integrated pest management ………………………….. Parked hTTps://www.abim.ch/fileadmin/abim/documents/presentations2016/3_Tetsuo_Wada_ABIM_2016.pdf hTTps://www.sumitomo-chem.co.jp/english/rd/report/files/docs/20090102_f7g.pdf
supersonico
21/1/2019
09:34
Thanks Wan. I don't think TTechnology is capable of anything in itself. Frankly it's an enigma to me how they can pushing forward the consumer opportunity vertical at all, except as a mainly empty and ineffective shop window front. So I hope the fact that it's private and therefore much less open to scrutiny is simply concealing the more substantial interests pushing to launch and distribute the product. Yes, apologies for the url.
brucie5
21/1/2019
09:27
Bruce...Yes, in the above post and previous posts e.g. post 189, I have tried to put some worth on the potential for a head lice product that was previously described as "efficacious, low-risk ingredients will provide the differentiator and sustainable competitive advantage required to be successful in this attractive market". If that still applies, the likes of Alliance will be concerned about such a disruptive product, especially given the head lice resistance issues suffered by most existing products(and having paid a large sum for the Vamousse brand!). Whether such scenarios are playing a part in the delay remains to be seen, but either way, a good distribution strategy and partner will be required. Thus, I am not sure TerpeneTech, in its present form (and cash), can deliver what is required for such a strategy. Thus, in one form or another, I am expecting change! PS...Please try using Tinyurl to convert long links, it then doesn't disrupt the width of the thread (it's free!) - hTTps://tinyurl.com/
wan
21/1/2019
08:14
Wan, not sure what you're intending to indicate here. Rate or volume of revenue growth... or the fact that it was acquired? - --------------------------------------------------------------------------------------------------------- Ok, think I've got it. Alliance acquired rights to Vamousse headlice treatment in 2017, for thirteen million. Seems to be a novel treatment which works through dehydrating the eggs. https://preview.tinyurl.com/y7gf45rn
brucie5
21/1/2019
07:24
I note the following excerpt from Alliance Pharma's Pre-Close Trading Update - 21 January 2019 ALLIANCE PHARMA PLC ("Alliance" or the "Group") Pre-Close Trading Update Vamousse™, acquired in December 2017, performed in line with expectations, achieving sales of £5.8m, up 16% on 2017 (under previous ownership), and up 18% on a constant currency basis. hTTps://otp.tools.investis.com/clients/uk/alliance_pharma/rns/regulatory-story.aspx?cid=1177&newsid=1226603
wan
20/1/2019
21:22
Come on Sipcam. Make us an offer we can't refuse. ;)
brucie5
20/1/2019
13:51
Anyone following the Missing $21 Trillion story?? hTTps://www.youtube.com/watch?time_continue=2665&v=V3eHf9JJRZs ………. Parked: Sipcam Nichino Brasil 2015 Sipcam and Nihon form Brazil jv Japanese company Nihon Nohyaku (Tokyo) and Italian company Sipcam (Milan) have formed a 50:50 joint venture in Brazil, Sipcam Nichino Brasil. The venture was formed in September last year to develop, market, distribute and formulate agrochemicals. The business’ 2013 turnover totalled some R$326 million (US$130 million at the current rate). The deal builds on Sipcam’s 35 years of operating in the country added to Nihon’s R&D knowhow developing proprietary products, proving “substantial synergy”, the companies say. The entity operates from Uberaba in Minas Gerais state. UPL (formerly United Phosphorus) sold its half of the joint venture, Sipcam UPL Brasil, to its partner, Sipcam, earlier last year. That partnership began with the Indian company’s acquisition of Italian agrochemical company Isagro’s 50% stake in the previously named Sipcam Isagro Brasil in 2011. hTTps://www.youtube.com/watch?v=Eqf9aBlDOzE hTTp://news.agropages.com/News/NewsDetail---22663.htm The company has a 50 partnership with the Japanese company Nihon Nohyaku Co. Ltd., which has traditionally developed new molecules. In what way can the Japanese company, which specializes in the sector, generate a competitive differential for Sipcam Nichino in Brazil? Sipcam Europe Further to the alliance signed in 2012 with the multinational Sumitomo Corporation and the research company Nihon Nohyaku Co.Ltd, Sipcam merged its distribution networks in Europe setting up the Holding Sipcam Europe S.p.A., which operates in Italy, Spain, Portugal, Great Britain, Greece and the Benelux countries. The majority is held by Sipcam. hTTp://www.sipcam-oxon.com/public/companies/ Map/ hTTp://www.betaitalia.it/UploadedFiles/difesadiserbo/SIPCAM_00_Capella_Gruppo.pdf hTTps://www.nichino-europe.com/
supersonico
20/1/2019
11:17
Investing, Agree if they are going to do this it should be substantive and publicity generating to be worthwhile. ………;……̷0;……R30;…. 'ideally by film' AR ;)
supersonico
20/1/2019
11:16
Either of you going?
brucie5
20/1/2019
10:51
Super I totally agree. No need going to a Proactive evening to announce TT. Eden has to deliver something to stimulate greater interest and investment in its share price. Sustaine™ would do that. But, they will need to expand that communication beyond the evening and an "update" video. The communication of Sustaine™ will need to be broader and deeper and those who don't know Eden at that stage will need the Company to deliver a comprehensive understanding, ideally by film, about who the Company is and why they are worth investing in.
investingisatrickygame
20/1/2019
09:49
The Proactive 7/2 presentation only makes sense to me if it is Preceded by Sustaine news imo. Clarity or progress news from TT would save the reputational challenged red faces and be a bonus so I think that's coming as well.
supersonico
20/1/2019
09:02
Take a trip back to 2014 and do your best Imagineering. hTTps://www.sumitomo-chem.co.jp/english/ir/event/files/docs/20140919e.pdf Business Strategy of the Health & Crop Sciences Sector. Ray Nishimoto Director & Managing Executive Officer Sumitomo Chemical September 19, 2014 Slide 28: Working with Monsanto..Top company in the world in Seeds & Non-selective herbicides ・RoundUp Ready (genetically modified organism) ・RoundUp (non-selective herbicides) but...ROUNDUP resistance problem is expanding ………………………………………………………………………. hTTps://www.giiresearch.com/report/kt455262-seed-treatment-market-report-forecasts-by-type.html Which seed treatment crop types will thrive from 2017-2027? Separate projections and analysis explore the potential Corn Soybean Wheat Cotton Rice Vegetables Other
supersonico
19/1/2019
22:59
Brucie5, I suspect in the knowns that we have and on the horizon right now, value in my opinion will likely rank as Sustaine Cedroz Bayer Mevalone Headlice I also suspect that any other strategic stake taken, should that happen, will revolve around Sustaine and it will have to be far greater than £2 million at 10.7p. Any such stake in Eden will surely be for right's granted and they as we suspect, should be very valuable. Super & AttyG, any thought's on the above?
investingisatrickygame
19/1/2019
21:32
A viable business model for a restaurant chain is very different to a business developing disruptive technologies. There is always the gap to cash earnings and that is the risk investors take on for a proportion of the future profits, expressed in a higher share price. I am open to the possibility of further funding, either in the form of a rights issue or further strategic investment by one of our partners, if that is what is needed to cross the line. However, before that, I would expect to see evidence of key milestones reached, including Bayer and TT launch, along with cedroz EPA, which together I suspect attract a higher share price, most probably in the twenties. This is before sustaine, which may in itself be the deal that catalyzes the further strategic investment, and a re-rating. In conclusion, and as I've said before, I see this year as pivotal to the investment case. And so while I will be keeping an eye on those mevalone sales, my main interest is to see those promises materialize.
brucie5
19/1/2019
20:33
With a viable business model, an increase in revenues means an increase in profit / reduction in losses and an increase in free cash generation / reduction in cash burn. When the opposite happens on a increase in revenue you know it is either a fraud or an uber dog.
sweet karolina
19/1/2019
20:29
It's all timing and what not... I don't know now if or when Eden will be a good investment?I've been involved in this share for 7ish years. The latest results/update is very disappointing but what's 2 more years (or more) I'll hold my small (value) holding as long as it takes. If there's no update around the proactive meeting then I imagine you (Jak) will make money ??.
timbo_slice
19/1/2019
18:56
Chris has, can you explain your enigmatic post. 'why jak would be worried..' But yes, there are climatic variables impacting on mevalone... Against presumably, growing take up and territories etc.
brucie5
19/1/2019
15:33
With the Bayer CAP narrative going into reverse (delays on 4, going to 3 formulation issue) along with Bayer selling Animal Health side of business I'm wild wondering if Sumitomo might be buying the rights to Eden CAP from Bayer.
supersonico
19/1/2019
14:50
Well done Super. Very interesting and maybe aligned.
investingisatrickygame
19/1/2019
12:59
Looked interesting, but be aware that the little knowledge I have is most definitely a Dangerous Rabbit hole... so be sceptical. I post a review of my work by a fan as a way of warning you of my unreliable nature: 'Some of the nonsense you come out with is laughable and you are misleading people; for whatever reason I have no idea but I am sure that most people realise that. I will leave you to it! You have a vivid imagination that is for sure' Mj You have been warned. ……………………………………………………………………………………………………………... SUMMIT AGRO USA LLC hTTp://www.summit-agro.co.jp/english/company/overview.html Our mission is to seek to contribute to people's lives and the environment, and to create ideal society. We will continue our untiring efforts to achieve this goal and improve our corporate value. We are a trading company of the Sumitomo Corporation Group specialized in chemicals and materials for agriculture, environmental health, and pet care products, and are engaged in the trading of those products within and outside Japan. Specifically, we export and import these products using the global network of Sumitomo Corporation (overseas offices and operating companies) and the Summit Agro sister companies and subsidiaries. We also sell crop protection products developed by our company and owned by Sumitomo Corporation in the Japanese market, as well as raw materials of household insecticides. We make an effort to sell Hartz Mountain's pet care products in Japan under a brand license deal. Hartz Mountain is a U.S. company acquired by Sumitomo Corporation. hTTps://www.linkedin.com/in/keith-branly-96a697/ hTTps://worldwide.espacenet.com/publicationDetails/description?CC=BR&NR=112018001265A2&KC=A2&FT=D&ND=3&date=20180911&;DB=&locale=en_EP# SUSPENSION CONCENTRATE BACKGROUND OF THE INVENTION [0002] Agrochemicals are typically available in a number of different physical forms and formulations. Some of these forms are intended to address the varying strengths and weaknesses of the active ingredient as well as the applicable regulations associated with that ingredient. Other forms address the area where the product is most likely to be used and the types of application equipment that tend to prevail in that region. High concentration formulations of single or multiple active ingredients are desirable for a variety of economic and environmental reasons, including the reduction of shipping and handling costs. Liquid pre-mix concentrates containing two or more active ingredients are useful in a wide variety of agricultural applications. For example, two or more pesticidal active ingredients may be combined in order to control a wider spectrum of pests, or to utilize multiple modes of action, compared to the individual active ingredients alone. …………………………. Did some one say ... Pipeline ?? hTTps://www.ds-pharma.com/profile/business/business_other.html Sumitomo Dainippon Pharma Products Food Ingredients and Chemical Product Materials The food ingredients and chemical product materials business is handled by Sumitomo Dainippon Pharma subsidiary DSP Gokyo Food & Chemical Co., Ltd. In the food ingredients and food additives business, the company develops and sells food ingredients and additives for use in manufacturing safe, high-quality foods. Products include polysaccharides, primarily GLYLOID® (tamarind seed gum), the first product of its kind successfully produced by the company on an industrial scale and seasonings such as soup or bouillon. Additionally, in the chemical product materials business, which includes pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials, the company is expanding to a wide range of customers by leveraging our unique technology and expertise, while cooperating with domestic and overseas suppliers. DSP GOKYO FOOD & CHEMICAL Co., Ltd. Animal Health Products The animal health products business is conducted by Sumitomo Dainippon Pharma subsidiary DS Pharma Animal Health Co., Ltd. The major products are veterinary medicines and other products for companion animals, primarily dogs and cats, as well as for livestock such as cattle, swine, poultry, horses and aquacultured fish. The company aims to commercialize cellular medicines for animals. DS Pharma Animal Health Co., Ltd. Diagnostics and Pharmaceuticals Sumitomo Dainippon Pharma subsidiary DS Pharma Biomedical Co., Ltd. conducts the diagnostics and Pharmaceuticals business. The company develops and supplies products such as point-of-care testing (POCT) diagnostics for infectious diseases (influenza, streptococcus, etc.), acute myocardial infarction, etc.; diagnostics to measure bone and calcium metabolism markers; diagnostics to measure drug concentration levels in the blood; high sensitivity products combining small immunofluorescence analyzers and special reagents. Furthermore, the company commenced manufacturing and selling of authorized generic (AG) pharmaceuticals in FY 2017.
supersonico
19/1/2019
09:13
Useful resource / Biopesticide reports and Growth Trends by Dunham and Trimmer. P42 Consolidation to continue in both industries. hTTp://dunhamtrimmer.com/wp-content/uploads/2017/07/NewAgIntlMagazineMarch2017-MandAsinBiologicals.pdf hTTp://dunhamtrimmer.com/publications-and-presentations/ Resources: Published Articles: Biopesticides for Seed Treatment Mergers & Acquisitions in Biostimulant and Biocontrol Sectors “The World of Semiochemicals” “ABIM 2015” (Contribution) MICROBIAL BIOPESTICIDES: A Key Role in the Multinational Portfolio Biocontrol in Asia Gaining Momentum Biopesticides: Killer Bugs for Hire Biopesticides: No Longer a Fringe Sector
supersonico
19/1/2019
00:17
hTTps://www.sumitomocorp.com/en/europe/news/release/2017/group/20170119 Expanding Business in Europe, the World Leader in Biocontrol Solutions Sumitomo Corporation (head office: Chuo-ku, Tokyo; President & CEO: Kuniharu Nakamura) has invested in Futureco Bioscience S.A. (head office: Barcelona, Spain; hereinafter “Futureco”) through its crop protection marketing company, Sumi Agro Europe Ltd. (head office: London, U.K.; hereinafter “SAE”). Futureco specializes in research, development and production of biocontrol products1 and biostimulants2 (together hereinafter “biocontrol solutions”). With this investment, SAE will access a strong discovery pipeline and manufacturing competence that will significantly enhance its portfolio in this key growth sector. SAE began marketing crop protection products in Europe, more than 25 years ago and today has a direct distribution presence in 16 countries through its subsidiary and affiliate companies. The wide portfolio and flexible supply options from Futureco provides an opportunity to strengthen SAE position as a provider of new technology solutions that are developed for local farming systems. The expansion of the business in biocontrol solutions is one of the key strategies of SAE, and is expected to bring about complementary synergy with its crop protection products in both product development and sales. Futureco will access the distribution network of SAE in Europe and Sumitomo Corporation worldwide for its existing portfolio and expects to accelerate the field development phase of its pipeline portfolio through collaboration with the SAE Development Division. Futureco is a family-owned company that has successfully targeted innovation in the sector of lower impact crop protection and plant health technologies, for more than twenty years. Collaboration with research institutes and universities, including the University of Barcelona, has been integrated with their practical agronomic knowledge to focus the discovery and selection of commercially valuable biocontrol solutions.
supersonico
Chat Pages: 247  246  245  244  243  242  241  240  239  238  237  236  Older
Your Recent History
LSE
EDEN
Eden
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190122 03:46:45